Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 179-188

  Di Costanzo, Francesco ^a   Gasperoni, Silvia ^a   Rotella, Virginia ^a   Di Costanzo, Federica ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Ospedale S Maria della Stella   (Italy)

Author keywords

Breast cancer; Chemotherapy; Nab paclitaxel

Indexed keywords

ALBUMIN; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NANOPARTICLE; NANOPARTICLE ALBUMIN BOUND PACLITAXEL; PACLITAXEL; POLYSORBATE 80; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SURFACTANT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSPNEA; ECONOMICS; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 77953472155     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/ott.s3863     Document Type: Review

References (62)

1. Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;227:665-667. (Pubitemid 9114288)
2. Ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665-685. (Pubitemid 36936530)
3. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344:1267-1272.
4. Boehnke Michaud L, Valero V, Hortobagyi GN. Risks and benefits of taxanes in breast and ovarian cancer. Drug Safety. 2000;23:401-428. (Pubitemid 30824856)
5. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia GroupB trial 9342. J Clin Oncol. 2004;22:2061-2068. (Pubitemid 41095138)
6. Sparreboom A, van Tellingen O, Nooijen WJ, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112-2115. (Pubitemid 26119912)
7. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19:125-141. (Pubitemid 32423718)
8. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-1598. (Pubitemid 32778603)
9. Jain RK: Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58-65.
10. Knemeyer I, Wientjes MG, Au JLS. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol. 1999;44:241-248. (Pubitemid 29350180)
11. Kumar GN, Walle UK, Bhalla KN, et al. Binding of Taxol to human plasma, albumin and alpha1-acid glycoprotein. Res Commun Chem Pathol Pharmacol. 1993;80:337-344.
12. Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res. 1998;4:1937-1942. (Pubitemid 28369178)
13. Postma TJ, Vermorken JB, Liefting AJM, et al. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6:489-494.
14. Onetto N, Canetta R, Winograd B, et al. Overview of taxol safety. J Natl Cancer Inst. 1993;15:131-139.
15. de Groen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med. 1987;317:861-866. (Pubitemid 17156729)
16. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther. 1994;268:1051-1056.
17. Aventis Pharmaceuticals Inc. Taxotere (docetaxel): prescribing information. Bridgewater, NJ: Aventis Pharmaceuticals; 2002.
18. Boer HM, Moorer-van Delft CM, Muller LJ, et al. Ultrastructural neuropathologic effects of Taxol on neurons of the fresh-water snail Lymnaea stagnalis. J Neurooncol. 1995;25:49-57.
19. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporine inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther. 1992;261:803-810.
20. Crown J, O'Leary M: The taxanes: an update. Lancet. 2000;355(9210):1176- 1178.
21. New PZ, Jackson CE, Rinaldi D, et al. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology. 1996;46:108-111. (Pubitemid 26156112)
22. Pronk LC, Hikens PH, van den Bent MJ, et al. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs. 1998;9:759-764.
23. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of kind. Ann Oncol. 1994;5:495-505. (Pubitemid 2112632)
24. Freilich RJ, Balmaceda C, Seidman AD, et al. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996;47:115-118. (Pubitemid 26243870)
25. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038-1044. (Pubitemid 34517637)
26. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59(7):1454-1457. (Pubitemid 29160110)
27. Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol. 1992;263(6 Pt 2):H1872-H1879. (Pubitemid 23030742)
28. Bouras T, Lisanti MP, Pestelli RG. Caveolin-1 in breast cancer. Cancer Biol Ther. 2004;3(10):931-941.
29. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4(8):1873-1880. (Pubitemid 28369170)
30. Roy V, Laplant BR, Gross GG, et al. for the North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albuminbound)- paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (NO531). Ann Oncol. 2009;20:449-453.
31. Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72(4):267-272. (Pubitemid 40342998)
32. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8(3):185-194.
33. Pelkmans L, Puntener D, Helenius A. Local actin polymerization ad dynamin recruitment in SV40 induced internalization of caveolae. Science. 2002;296(5567):535-539. (Pubitemid 34408673)
34. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus plysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008;19(9):899-909.
35. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-lung cancer. Ann Oncol. 2006;17(8):1263- 1268. (Pubitemid 44288216)
36. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-1324. (Pubitemid 43342524)
37. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(Suppl 3):11-16.
38. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333: 328-335. (Pubitemid 40848295)
39. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez- Soler R, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005;65:2854-2860. (Pubitemid 40490089)
40. Miyahara Y, Yoshida S, Motoyama S, Tateiwa Y, Hamana S, Maruo T. Effect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma. Eur J Gynaecol Oncol. 2004;25:33-39. (Pubitemid 38165917)
41. Wild R, Dings RP, Subramanian I, et al. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004;110:343-351. (Pubitemid 38649884)
42. Mills PJ, Parker B, Jones V, Adler KA, Perez CJ, Johnson S, et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin Cancer Res. 2004;10:4998-5003. (Pubitemid 39099773)
43. Riedel F, Gotte K, Goessler U, Sadick H, et al. Targeting chemotherapyinduced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. Anticancer Res. 2004;24:2179-2183. (Pubitemid 39166292)
44. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369-3372. (Pubitemid 32695027)
45. Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V. Human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia. 2008;10:613-623.
46. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23:7785-7793. (Pubitemid 46657375)
47. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethilated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007). Cancer. 2001;92:2592-2602.
48. Damascelli B, Patelli G, Lanocita R, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue:preliminary findings. Am J Roentgenol. 2003;181: 253-260. (Pubitemid 36741497)
49. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab paclitaxel. Clin Cancer Res. 2008;14(13):4200-4205.
50. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23(25):6019-6026. (Pubitemid 46300219)
51. Blum JL, Savin MA, Edelman G, Pippen JE, Robert N, Sandbach J. Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract]. J Clin Oncol. 2004;22(14 Suppl): Abstract 543.
52. Link JS, Waisman JR, Nguyen B, et al. Bevacizumab and albumine-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer. 2007;(10):779-783. (Pubitemid 350086122)
53. Gradishar W, Cortes J. Clinical efficacy and emerging therapeutic utilization of novel taxanes. EJC Supplements. 2008;10(6):12-21.
54. Conlin AK, Seidman AD, Moynahan, et al. Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2 negative metastatic breast cancer: An initial interim safety report [abstract]. J Clin Oncol. 2007;25(18S part I):1104.
55. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV. Phase II study of weekly albumin - bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;(11):580-586.
56. Schwartzberg LS, Arena F, Mintzer D, et al. Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC):interim results [abstract]. Breast Cancer Res Treat. 2006;100(Suppl 1):1096.
57. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7768-7771. (Pubitemid 46657376)
58. Gradishar W, Krasnojon D, Cheporov S. Manikhas G, Clawson A, Hawkins MJ. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol. 2007;25(Suppl):18S.
59. Dranitsaris G, Cottrel W, Spirovski B, et al. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract. 2008;Nov 26 (Epub ahead of print).
60. Robidoux A, Buyse M, Buzdar A, et al. Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation research programs (FRP) [abstract]. Breast Cancer Res Treat. 2006;100 (Suppl 1):3068 (abstract).
61. Somlo G, Paz B, Shen J, et al. A randomized phase II neoadjuvant trial in patients with stage II-III and inflammatory breast cancer. Breast Cancer Res Treat. 2007;106:5073.
62. Daniel BR, Doss H, Gian V, et al. Biweekly neoadjuvant gemcitabine, epirubicin, and nano-particle albumin bound (nab) paclitaxel (GEA) with tumor SPARC analysis correlated with pathological responses: Results of a multicenter phase II trial. J Clin Oncol. 2007;25(18S part I):11060.